Gray Katherine, Sheehan Whitley, McCracken Laura, Krogh Klaus, Sachdeva Rahul, Krassioukov Andrei V
Faculty of Medicine, University of British Columbia (UBC), Vancouver, BC, Canada.
International Collaboration on Repair Discoveries (ICORD), Faculty of Medicine, UBC, Vancouver, BC, Canada.
Spinal Cord. 2023 Jan;61(1):1-7. doi: 10.1038/s41393-022-00840-8. Epub 2022 Aug 12.
Systematic review.
To systematically review the evidence on the use of local analgesics, specifically lidocaine or bupivacaine, to prevent autonomic dysreflexia (AD) during iatrogenic procedures or bowel and bladder care routines in individuals with spinal cord injury (SCI).
A keyword search of MEDLINE, CINAHL, CENTRAL, Cochrane Reviews, PsycInfo, Embase, and Web of Science databases identified all English-language studies evaluating the efficacy of local analgesics in reducing AD. Included studies were either randomized controlled trials (RCTs) or quasi-experimental studies. Participants were adults with chronic SCI who received local analgesics prior to AD-triggering procedures or routines. Additionally, studies were required to report blood pressure values as an outcome. The methodology of this review followed the PRISMA checklist and was registered with PROSPERO (CRD42021219506).
Four RCTs and two quasi-experimental studies met inclusion criteria. Results were narratively synthesized as meta-analysis was not possible due to heterogeneity across studies included in the review. All six studies administered lidocaine. Lidocaine was found to have a beneficial effect on AD in three studies, no effect in two studies and a detrimental effect in one study.
Presently, RCTs and quasi-experimental studies on the use of lidocaine for reducing AD in individuals with SCI had small sample sizes and opposing findings. There is a strong need for definitive, well-monitored clinical trials with adequate sample sizes. Presently there is not enough compelling evidence to support or refute recommendations for the use of lidocaine from the AD management clinical practice guidelines.
系统评价。
系统评价局部镇痛药(特别是利多卡因或布比卡因)在脊髓损伤(SCI)患者进行医源性操作或肠道及膀胱护理常规时预防自主神经反射异常(AD)的证据。
通过对MEDLINE、CINAHL、CENTRAL、Cochrane系统评价、PsycInfo、Embase和科学网数据库进行关键词检索,确定了所有评估局部镇痛药在降低AD方面疗效的英文研究。纳入的研究为随机对照试验(RCT)或准实验研究。参与者为成年慢性SCI患者,在触发AD的操作或常规护理前接受局部镇痛药治疗。此外,要求研究报告血压值作为一项结果指标。本评价的方法遵循PRISMA清单,并在PROSPERO(CRD42021219506)注册。
四项RCT和两项准实验研究符合纳入标准。由于纳入评价的研究存在异质性,无法进行荟萃分析,故对结果进行叙述性综合。所有六项研究均使用了利多卡因。在三项研究中发现利多卡因对AD有有益作用,在两项研究中无作用,在一项研究中有有害作用。
目前,关于使用利多卡因降低SCI患者AD的RCT和准实验研究样本量较小且结果相互矛盾。迫切需要进行样本量充足、严格监测的确定性临床试验。目前没有足够令人信服的证据支持或反驳AD管理临床实践指南中关于使用利多卡因的建议。